Daniel Barber Insider Profile
4 Followers
Daniel Barber, President & CEO at Aquestive Therapeutics, holds 635.57K shares in Aquestive Therapeutics (Ticker: AQST). Most recently, Daniel Barber Sold 25,000 shares of Aquestive Therapeutics on Jun 16, 2026 for an estimated value of $104.00K.
Daniel Barber Aquestive Therapeutics (AQST)President & CEO
Aquestive Therapeutics (AQST)
President & CEO
Ranked #10,387 out of 108,079 Corporate Insiders
Profitable Transactions
2 out of 5 Profitable Transactions
Average Return
+46.20%
Average return per transaction
Time Frame
Compare to
Insider Roles
President & CEO
Roles that Daniel Barber holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jun 10, 2022 - Jun 10, 2023
Return:+145.60%
The most profitable trade made by Daniel Barber
Daniel Barber's Trading History
List of latest transactions for each holding click on a transaction to see Daniel Barber's performance on stock
You May Also Like
Daniel Barber insider profile FAQ
What is the percentage of profitable transactions made by Daniel Barber?
The percentage of profitable transactions made by Daniel Barber is 40%.
What is the average return per transaction made by Daniel Barber?
The average return per transaction made by Daniel Barber is 46.20%.
What stocks does Daniel Barber hold?
Daniel Barber holds: AQST stocks.
What was Daniel Barber’s latest transaction?
Daniel Barber latest transaction was an Informative Sell of $104.00K.
What was Daniel Barber's most profitable transaction?
Daniel Barber’s most profitable transaction was an Informative Buy of AQST stock on June 10, 2022. The return on the trade was 145.60%.
What is Daniel Barber's role in Aquestive Therapeutics?
Daniel Barber's role in Aquestive Therapeutics is President & CEO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.